# INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma

> **NCT03837509** · PHASE1,PHASE2 · TERMINATED · sponsor: **Incyte Corporation** · enrollment: 15 (actual)

## Conditions studied

- Relapsed or Refractory Multiple Myeloma

## Interventions

- **DRUG:** INCB001158
- **BIOLOGICAL:** Daratumumab SC

## Key facts

- **NCT ID:** NCT03837509
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-09-25
- **Primary completion:** 2022-04-05
- **Final completion:** 2022-04-05
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** This decision follows recruitment difficulties. No safety-related concerns impacted this decision.
- **Last updated:** 2025-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03837509

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03837509, "INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT03837509. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*